Suppr超能文献

经口给予特异性抗体可增强致癌物的排泄。

Peroral administration of specific antibody enhances carcinogen excretion.

作者信息

Rasmussen M V, Silbart L K

机构信息

Department of Animal Science, University of Connecticut, CANR, Storrs 06269, USA.

出版信息

J Immunother. 1998 Nov;21(6):418-26. doi: 10.1097/00002371-199811000-00003.

Abstract

Ingested carcinogens may exert effects directly on the gastrointestinal epithelium or after absorption and transport to other tissues. To determine the effect of anti-carcinogen antibody ingestion on dietary carcinogen excretion, a mixture of specific IgA or IgG and the model carcinogen 125I-N-2-(4-hydroxyphenyl-acetamido) fluorene (125I-pHP-AAF) was perorally administered to mice. These mice excreted more total and antibody-bound radiotracer in feces compared with controls given a similar mixture containing nonspecific antibody. In addition, urinary radiotracer excretion was reduced by 96% in specific-antibody dosed mice, indicating reduced gastrointestinal absorption of 125I-pHP-AAF. Reduced radiotracer absorption was also reflected by a 56% reduction in radiotracer content in tissues from mice receiving specific antibody. Other mice received peroral IgA before i.p. injection of 125I-PH-AAF. Specific antibody treatment consistently increased intraluminal radiotracer sequestration, as indicated by the level of total and antibody-bound radiotracer partitioning to aqueous fecal extracts. Similarly, when a mixture of 125I-pHP-AAF and IgG were injected directly into the small intestine, more radioactivity appeared in the feces of mice given specific antibody. High-performance liquid chromatography analysis of aqueous fecal extracts indicated that the majority of fecal radiotracer from specific-antibody dosed mice was unmetabolized parent compound. Thus, peroral administration of AAF-specific antibodies mixed with 125I-pHP-AAF decreased gastrointestinal absorption and increased fecal excretion of the radiotracer, suggesting a novel mechanism for protection against environmental carcinogens.

摘要

摄入的致癌物可能直接作用于胃肠道上皮,或在吸收并转运至其他组织后发挥作用。为了确定摄入抗癌原抗体对膳食致癌物排泄的影响,将特异性IgA或IgG与模型致癌物125I-N-2-(4-羟基苯基-乙酰胺基)芴(125I-pHP-AAF)的混合物经口给予小鼠。与给予含有非特异性抗体的类似混合物的对照组相比,这些小鼠粪便中排泄的总放射性示踪剂和与抗体结合的放射性示踪剂更多。此外,给予特异性抗体的小鼠尿中放射性示踪剂排泄减少了96%,表明125I-pHP-AAF的胃肠道吸收减少。接受特异性抗体的小鼠组织中放射性示踪剂含量降低了56%,也反映出放射性示踪剂吸收减少。其他小鼠在腹腔注射125I-PH-AAF之前经口给予IgA。特异性抗体处理持续增加肠腔内放射性示踪剂的滞留,这由粪便水提取物中总放射性示踪剂和与抗体结合的放射性示踪剂的分配水平表明。同样,当将125I-pHP-AAF和IgG的混合物直接注入小肠时,给予特异性抗体的小鼠粪便中出现更多放射性。粪便水提取物的高效液相色谱分析表明,来自给予特异性抗体的小鼠的粪便中大部分放射性示踪剂是未代谢的母体化合物。因此,将AAF特异性抗体与125I-pHP-AAF混合经口给药可减少胃肠道吸收并增加放射性示踪剂的粪便排泄,提示了一种预防环境致癌物的新机制。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验